Contribution of autopsies to detect the presence of metastases in low-grade prostate cancer
Keywords:
Próstata, cáncer, Gleason, autopsiaDownloads
Download data is not yet available.
References
1. Eggener SE, Berlin A, Vickers AJ, Paner GP, Wolinsky H, Cooperberg MR. Low-grade prostate cancer: time to stop calling it cancer. J Clin Oncol. 2022;40(27):3110-3114. DOI: https://ascopubs.org/doi/10.1200/JCO.22.00123
2. Labbate CV, Paner GP, Eggener SE. Should Grade Group 1 (GG1) be called cancer? World J Urol. 2022;40(1):15-19. DOI: https://link.springer.com/article/10.1007/s00345-020-03583-4
3. Epstein JI, Kibel AS. Renaming Gleason score 6 prostate to noncancer: A flawed idea scientifically and for patient care. J Clin Oncol. 2022;40(27):3106-3109. DOI: https://ascopubs.org/doi/10.1200/JCO.22.00926
4. Iczkowski KA, Molina M, Egevad L, Bostwick DG, van Leenders GLJLH, La Rosa FG, et al. Low-grade prostate cancer should still be labeled cancer. BJU Int. 2022. DOI: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.15886
5. Netto GJ, Amin MB, Compérat EM, Gill AJ, Hartmann A, Moch H, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. 2022;S0302-2838(22)02644-6. DOI: https://doi.org/10.1016/j.eururo.2022.09.015
6. Alam MU, Kumar J, Norez D, Woolfe J, Tanneru K, Jazayeri SB, et al. Natural history, and impact of surgery and radiation on survival outcomes of men diagnosed with low-grade prostate cancer at ≤ 55 years of age: a 25-year follow-up of > 60,000 men. Int Urol Nephrol. 2022; 29 de septiembre. DOI: https://doi.org/10.1007/s11255-022-03363-6
7. Thomsen FB, Westerberg M, Garmo H, Robinson D, Holmberg L, Ulmert HD, et al. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason grade: nationwide, population-based register study. PLoS One. 2020;15(1):e0228447. DOI: https://doi.org/10.1371/journal.pone.0228447
8. Le Bihan E, Derman J, Salomon L, De La Taille A, Irani J, Lebacle C. Radical prostatectomy in patients with Gleason 6 (ISUP 1) prostate cancer: 10-year follow up. Prog Urol. 2022;32(2):108-14. DOI: https://doi.org/10.1016/j.purol.2021.10.008
9. Naik N, Tokas T, Shetty DK, Hameed BMZ, Shastri S, Shah MJ, et al. Role of Deep Learning in Prostate Cancer Management: Past, Present and Future Based on a Comprehensive Literature Review. J Clin Med. 2022;11(13):3575. DOI: https://doi.org/10.3390/jcm11133575
10. Hurtado de Mendoza Amat JD, Montero González TJ. El diagnóstico correcto de las causas de muerte ayuda a salvar vidas. Revista Cubana de Medicina Militar. 2020 [acceso 12/10/2022];49(4):e0200629. Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/629
2. Labbate CV, Paner GP, Eggener SE. Should Grade Group 1 (GG1) be called cancer? World J Urol. 2022;40(1):15-19. DOI: https://link.springer.com/article/10.1007/s00345-020-03583-4
3. Epstein JI, Kibel AS. Renaming Gleason score 6 prostate to noncancer: A flawed idea scientifically and for patient care. J Clin Oncol. 2022;40(27):3106-3109. DOI: https://ascopubs.org/doi/10.1200/JCO.22.00926
4. Iczkowski KA, Molina M, Egevad L, Bostwick DG, van Leenders GLJLH, La Rosa FG, et al. Low-grade prostate cancer should still be labeled cancer. BJU Int. 2022. DOI: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.15886
5. Netto GJ, Amin MB, Compérat EM, Gill AJ, Hartmann A, Moch H, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. 2022;S0302-2838(22)02644-6. DOI: https://doi.org/10.1016/j.eururo.2022.09.015
6. Alam MU, Kumar J, Norez D, Woolfe J, Tanneru K, Jazayeri SB, et al. Natural history, and impact of surgery and radiation on survival outcomes of men diagnosed with low-grade prostate cancer at ≤ 55 years of age: a 25-year follow-up of > 60,000 men. Int Urol Nephrol. 2022; 29 de septiembre. DOI: https://doi.org/10.1007/s11255-022-03363-6
7. Thomsen FB, Westerberg M, Garmo H, Robinson D, Holmberg L, Ulmert HD, et al. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason grade: nationwide, population-based register study. PLoS One. 2020;15(1):e0228447. DOI: https://doi.org/10.1371/journal.pone.0228447
8. Le Bihan E, Derman J, Salomon L, De La Taille A, Irani J, Lebacle C. Radical prostatectomy in patients with Gleason 6 (ISUP 1) prostate cancer: 10-year follow up. Prog Urol. 2022;32(2):108-14. DOI: https://doi.org/10.1016/j.purol.2021.10.008
9. Naik N, Tokas T, Shetty DK, Hameed BMZ, Shastri S, Shah MJ, et al. Role of Deep Learning in Prostate Cancer Management: Past, Present and Future Based on a Comprehensive Literature Review. J Clin Med. 2022;11(13):3575. DOI: https://doi.org/10.3390/jcm11133575
10. Hurtado de Mendoza Amat JD, Montero González TJ. El diagnóstico correcto de las causas de muerte ayuda a salvar vidas. Revista Cubana de Medicina Militar. 2020 [acceso 12/10/2022];49(4):e0200629. Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/629
Downloads
Published
2023-01-10
How to Cite
1.
Farre Pueyo X, González Rivero M del C, Serdà Ferrer B-C, Marcos Gragera R, Fuentes Raspall R, Baltasar Bagué A. Contribution of autopsies to detect the presence of metastases in low-grade prostate cancer. Rev. Cubana Urol. [Internet]. 2023 Jan. 10 [cited 2024 Dec. 22];12(1):e914. Available from: https://revurologia.sld.cu/index.php/rcu/article/view/914
Issue
Section
Letters
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cual estará simultáneamente sujeto a la Licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
